Antiangiogenic Agents in Cancer Therapy (Cancer Drug Discovery and Development)

Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished , where the experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of their role in cancer treatment and novel drug development. In Antiangiogenic Agents in Cancer Therapy, Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished, where the experimental therapeutics of antiangiogenic agents are going, and the continuing evolution of their role in cancer treatment and novel drug development. Comprehensive and up-to-date, this book constitutes a key resource-rich in novel means and methods-for the clinical development of this important, highly promising new class of anticancer drugs Significant advances have been made in our understanding of angiogenesis, the process of blood vessel growth, and its relation to tumor growth. This volume describes the current understanding of tumor growth and its dependence on vascular development as well as the present status of antiangiogenic agents in preclinical and clinical development and what is known about the mechanisms by which these molecules interfere with tumor vascular growth. Significant recent progress in cancer therapy has been made in the area of angiogenesis and the control and inhibition of tumor growth. This book reviews what has been accomplished in the area of angiogenesis, where experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of the means and methods of cancer treatment and new drug development. Cancer researchers and clinicians will find this book an indispensable reference and guide to an exciting new field Pt. 1. Antiangiogenic Factors And Tumor Vasculature -- Pt. 2. Antiangiogenic Agents -- Pt. 3. In Vivo Studies And Clinical Trials. Edited By Beverly A. Teicher. Includes Index. Includes Bibliographical References And Index.